Gender differences in 12-week antidepressant treatment outcomes for a naturalistic secondary care cohort: the CRESCEND study - PubMed (original) (raw)
Gender differences in 12-week antidepressant treatment outcomes for a naturalistic secondary care cohort: the CRESCEND study
Su-Jin Yang et al. Psychiatry Res. 2011.
Abstract
This study aimed to determine whether men and women with depression differ in socio-demographic, treatment-related characteristics, and in their responses to treatment with antidepressants, as well as to explore differences in treatment outcomes by menopausal status. From a nationwide sample of 18 hospitals in South Korea, 723 depressive patients were recruited. After baseline evaluation, they received naturalistic clinician-determined antidepressant interventions. Assessment scales for evaluating depression (HAMD), anxiety (HAMA), global severity (CGI-s), and functioning (SOFAS) were administered at baseline and re-evaluated at 1, 2, 4, 8, and 12 weeks later. At baseline, women were older, less educated, less likely to be employed, had lower income, were more likely to be married, and had longer illness duration than men. There were no gender differences in the treatment-regime received. After adjustment for baseline status, women were more likely to achieve HAMD remission (OR=1.51), HAMD response (OR=1.64), and HAMA response (OR=1.61). Women also experienced shorter times to HAMD response, HAMA response, and CGI-s remission. Postmenopausal women showed higher HAMA response with newer dual action antidepressants than premenopausal women. Women were found to have better outcomes following antidepressant treatment than men, and postmenopausal women had a better response on anxiety symptoms with newer dual action antidepressants.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
Similar articles
- Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects.
Pae CU, Mandelli L, Kim TS, Han C, Masand PS, Marks DM, Patkar AA, Steffens DC, De Ronchi D, Serretti A. Pae CU, et al. Biomed Pharmacother. 2009 Mar;63(3):228-35. doi: 10.1016/j.biopha.2008.03.010. Epub 2008 Apr 30. Biomed Pharmacother. 2009. PMID: 18502089 Clinical Trial. - Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women.
Pae CU, Mandelli L, Han C, Ham BJ, Masand PS, Patkar AA, Steffens DC, De Ronchi D, Serretti A. Pae CU, et al. Neuro Endocrinol Lett. 2008 Aug;29(4):500-6. Neuro Endocrinol Lett. 2008. PMID: 18766158 Clinical Trial. - Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M. Henkel V, et al. J Affect Disord. 2009 Jun;115(3):439-49. doi: 10.1016/j.jad.2008.10.011. Epub 2008 Nov 22. J Affect Disord. 2009. PMID: 19027961 - Depression and the menopause: why antidepressants are not enough?
Graziottin A, Serafini A. Graziottin A, et al. Menopause Int. 2009 Jun;15(2):76-81. doi: 10.1258/mi.2009.009021. Menopause Int. 2009. PMID: 19465674 Review. - Treatment of depression--newer pharmacotherapies.
Mulrow CD, Williams JW Jr, Trivedi M, Chiquette E, Aguilar C, Cornell JE, Badgett R, Noël PH, Lawrence V, Lee S, Luther M, Ramirez G, Richardson WS, Stamm K. Mulrow CD, et al. Psychopharmacol Bull. 1998;34(4):409-795. Psychopharmacol Bull. 1998. PMID: 10513454 Review.
Cited by
- The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment.
Giménez-Palomo A, Dodd S, Anmella G, Carvalho AF, Scaini G, Quevedo J, Pacchiarotti I, Vieta E, Berk M. Giménez-Palomo A, et al. Front Psychiatry. 2021 Jul 6;12:546801. doi: 10.3389/fpsyt.2021.546801. eCollection 2021. Front Psychiatry. 2021. PMID: 34295268 Free PMC article. Review. - Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
Jones RR, Freeman MP, Kornstein SG, Cooper K, Daly EJ, Canuso CM, Nicholson S. Jones RR, et al. Arch Womens Ment Health. 2022 Apr;25(2):313-326. doi: 10.1007/s00737-021-01185-6. Epub 2022 Jan 1. Arch Womens Ment Health. 2022. PMID: 34973081 Free PMC article. Clinical Trial. - Review of Cohort Studies for Mood Disorders.
Jeon HJ, Baek JH, Ahn YM, Kim SJ, Ha TH, Cha B, Moon E, Kang HJ, Ryu V, Cho CH, Heo JY, Kim K, Lee HJ; Mood Disorders Cohort Research Consortium (MDCRC) Group. Jeon HJ, et al. Psychiatry Investig. 2016 May;13(3):265-76. doi: 10.4306/pi.2016.13.3.265. Epub 2016 May 18. Psychiatry Investig. 2016. PMID: 27247592 Free PMC article. Review. - Creatine target engagement with brain bioenergetics: a dose-ranging phosphorus-31 magnetic resonance spectroscopy study of adolescent females with SSRI-resistant depression.
Kondo DG, Forrest LN, Shi X, Sung YH, Hellem TL, Huber RS, Renshaw PF. Kondo DG, et al. Amino Acids. 2016 Aug;48(8):1941-54. doi: 10.1007/s00726-016-2194-3. Epub 2016 Feb 23. Amino Acids. 2016. PMID: 26907087 Free PMC article. Clinical Trial. - Sampling bias in an internet treatment trial for depression.
Donkin L, Hickie IB, Christensen H, Naismith SL, Neal B, Cockayne NL, Glozier N. Donkin L, et al. Transl Psychiatry. 2012 Oct 23;2(10):e174. doi: 10.1038/tp.2012.100. Transl Psychiatry. 2012. PMID: 23092978 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical